By Matt Grossman 



  Sanofi's Sarclisa, an immunotherapy for patients with multiple myeloma, has been approved by Canada's health authority, Sanofi said Wednesday. 


  The treatment was approved to treat patients who have had at least two prior therapies including lenalidomide and a proteasome inhibitor. Sarclisa was approved to be used in conjunction with pomalidomide and dexamethasone. 


  The drug's approval was based on a study that showed statistically significant improvement in patients' progression-free survival, Sanofi said. 


  Write to Matt Grossman at matt.grossman@wsj.com